CSL Limited Annual Report 2021/22 5 Another example of a valuable investment relates to improving our donors’ experience when they visit our centres. Plasma donors are a fundamental part of our business, and without thempatients would not have access to life-changing medicines. In order to optimise their experience in our centres, we are employing a new plasmapheresis platformutilising technology to support a safe, efficient and improved experience for plasma donors, as well as a better process for CSL Plasma employees. We will introduce this new technology across our 300 US centres in the future. A Promising Future In closing, I would like to thank our people, shareholders, partners, plasma donors and the many other stakeholders who allow us to bring people and science together to execute on our strategy. This combination helps us to achieve our purpose, which is to develop and deliver innovative medicines that help people with serious and life-threatening conditions live full lives and protect the health of communities around the world. While we are not immune to the macroeconomic environment, I can assure you we will continue to operate with resilience, integrity and agility and deliver sustainable growth Paul Perreault CEO and MD Acquisition of Vifor Pharma We recently announced the acquisition of Vifor Pharma (Vifor), a leading Swiss based company. Vifor has a world-leading iron replacement platform for treatment of diseases such as iron deficiency anaemia and continues to generate extensive clinical data in related areas of high unmet medical need, such as iron deficiency in heart failure and patient blood management. Through its extensive dialysis portfolio, Vifor has built a strong presence in renal diseases which continues to benefit from the introduction of novel therapies impacting disease progression. A cornerstone of Vifor’s growth strategy has been its strategic partnerships, which have allowed Vifor to both broaden its portfolio and provide patients access to the treatments they need. The Vifor business enhances CSL’s established focus on protecting the health of patients with a range of rare and serious medical conditions. Some of the strategic benefits of CSL’s acquisition of Vifor include: • Strengthening CSL’s Value driven strategy: Vifor adds a durable and growing business with leadership positions across complementary and adjacent franchises, delivering greater benefit to patients. • Combined with CSL’s R&D capabilities and financial scale, it enables a significant renal disease franchise to be established in this large and growing market. • Extends the reach of CSL’s high value pipeline: Together, CSL and Vifor will have a complementary portfolio and enhanced access to unique patient populations for future clinical studies. We look forward to aligning the rebrand of Vifor to CSL Vifor and integrating the business within CSL’s organisational structure and our 2030 Strategy. CSL People & Culture Patients and Public Health • Immunology • Haematology • Transplant • Respiratory • Cardiovascular and Metabolic • Influenza • Nephrology/Dialysis Efficiency & Focus Innovation Sustainable Growth Digital Transformation Reliable Supply • Products • Delivery • Services • Technology • Yield • Technology • Operational Excellence • Capital Project Execution • Partnerships • Plasma • Recombinants • Cell and Gene Therapy • Influenza Vaccines • Iron Therapy • Business Model • Connected Healthcare • New Capabilities CSL’s 2030 strategy with Vifor
RkJQdWJsaXNoZXIy MjE2NDg3